Cargando…

Evaluation of the FACSPresto, a New Point of Care Device for the Enumeration of CD4% and Absolute CD4+ T Cell Counts in HIV Infection

INTRODUCTION: Enumeration of CD4+ T lymphocytes is important for pre-ART disease staging and screening for opportunistic infections, however access to CD4 testing in resource limited settings is poor. Point of care (POC) technologies can facilitate improved access to CD4 testing. We evaluated the an...

Descripción completa

Detalles Bibliográficos
Autores principales: Makadzange, Azure Tariro, Bogezi, Carola, Boyd, Kathryn, Gumbo, Anesu, Mukura, Dorinda, Matubu, Allen, Ndhlovu, Chiratidzo Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936750/
https://www.ncbi.nlm.nih.gov/pubmed/27388763
http://dx.doi.org/10.1371/journal.pone.0157546
_version_ 1782441608532197376
author Makadzange, Azure Tariro
Bogezi, Carola
Boyd, Kathryn
Gumbo, Anesu
Mukura, Dorinda
Matubu, Allen
Ndhlovu, Chiratidzo Ellen
author_facet Makadzange, Azure Tariro
Bogezi, Carola
Boyd, Kathryn
Gumbo, Anesu
Mukura, Dorinda
Matubu, Allen
Ndhlovu, Chiratidzo Ellen
author_sort Makadzange, Azure Tariro
collection PubMed
description INTRODUCTION: Enumeration of CD4+ T lymphocytes is important for pre-ART disease staging and screening for opportunistic infections, however access to CD4 testing in resource limited settings is poor. Point of care (POC) technologies can facilitate improved access to CD4 testing. We evaluated the analytical performance of a novel POC device the FACSPresto compared to the FACSCalibur as a reference standard and to the PIMA, a POC device in widespread use in sub-Saharan Africa. METHOD: Specimens were obtained from 253 HIV infected adults. Venous blood samples were analyzed on the FACSPresto and the FACSCalibur, in a subset of 41 samples additional analysis was done on the PIMA. RESULTS: The absolute CD4 count results obtained on the FACSPresto were comparable to those on the FACSCalibur with low absolute (9.5cells/μl) and relative bias (3.2%). Bias in CD4% values was also low (1.06%) with a relative bias of 4.9%. The sensitivity was lower at a CD4 count threshold of ≤350cells/μl compared with ≤500cells/μl (84.9% vs. 92.8%) resulting in a high upward misclassification rate at low CD4 counts. Specificity at thresholds of ≤350cells/μl and ≤500cells/μl were 96.6% and 96.8% respectively. The PIMA had a high absolute (-68.6cells/μl) and relative bias (-10.5%) when compared with the FACSCalibur. At thresholds of ≤350cells/μl and ≤500cells/μl the sensitivity was 100% and 95.5% respectively; specificity was 85.7% and 84.2% respectively. The coefficients of repeatability were 4.13%, 5.29% and 9.8% respectively. DISCUSSION: The analytic performance of the FACSPresto against the reference standard was very good with better agreement and precision than the PIMA. The FACSPresto had comparable sensitivity at a threshold of 500 cells/μl and better specificity than the PIMA. However the FACSPresto showed reduced sensitivity at low CD4 count thresholds. CONCLUSION: The FACSPresto can be reliably used as a POC device for enumerating absolute CD4 count and CD4% values.
format Online
Article
Text
id pubmed-4936750
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49367502016-07-22 Evaluation of the FACSPresto, a New Point of Care Device for the Enumeration of CD4% and Absolute CD4+ T Cell Counts in HIV Infection Makadzange, Azure Tariro Bogezi, Carola Boyd, Kathryn Gumbo, Anesu Mukura, Dorinda Matubu, Allen Ndhlovu, Chiratidzo Ellen PLoS One Research Article INTRODUCTION: Enumeration of CD4+ T lymphocytes is important for pre-ART disease staging and screening for opportunistic infections, however access to CD4 testing in resource limited settings is poor. Point of care (POC) technologies can facilitate improved access to CD4 testing. We evaluated the analytical performance of a novel POC device the FACSPresto compared to the FACSCalibur as a reference standard and to the PIMA, a POC device in widespread use in sub-Saharan Africa. METHOD: Specimens were obtained from 253 HIV infected adults. Venous blood samples were analyzed on the FACSPresto and the FACSCalibur, in a subset of 41 samples additional analysis was done on the PIMA. RESULTS: The absolute CD4 count results obtained on the FACSPresto were comparable to those on the FACSCalibur with low absolute (9.5cells/μl) and relative bias (3.2%). Bias in CD4% values was also low (1.06%) with a relative bias of 4.9%. The sensitivity was lower at a CD4 count threshold of ≤350cells/μl compared with ≤500cells/μl (84.9% vs. 92.8%) resulting in a high upward misclassification rate at low CD4 counts. Specificity at thresholds of ≤350cells/μl and ≤500cells/μl were 96.6% and 96.8% respectively. The PIMA had a high absolute (-68.6cells/μl) and relative bias (-10.5%) when compared with the FACSCalibur. At thresholds of ≤350cells/μl and ≤500cells/μl the sensitivity was 100% and 95.5% respectively; specificity was 85.7% and 84.2% respectively. The coefficients of repeatability were 4.13%, 5.29% and 9.8% respectively. DISCUSSION: The analytic performance of the FACSPresto against the reference standard was very good with better agreement and precision than the PIMA. The FACSPresto had comparable sensitivity at a threshold of 500 cells/μl and better specificity than the PIMA. However the FACSPresto showed reduced sensitivity at low CD4 count thresholds. CONCLUSION: The FACSPresto can be reliably used as a POC device for enumerating absolute CD4 count and CD4% values. Public Library of Science 2016-07-07 /pmc/articles/PMC4936750/ /pubmed/27388763 http://dx.doi.org/10.1371/journal.pone.0157546 Text en © 2016 Makadzange et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Makadzange, Azure Tariro
Bogezi, Carola
Boyd, Kathryn
Gumbo, Anesu
Mukura, Dorinda
Matubu, Allen
Ndhlovu, Chiratidzo Ellen
Evaluation of the FACSPresto, a New Point of Care Device for the Enumeration of CD4% and Absolute CD4+ T Cell Counts in HIV Infection
title Evaluation of the FACSPresto, a New Point of Care Device for the Enumeration of CD4% and Absolute CD4+ T Cell Counts in HIV Infection
title_full Evaluation of the FACSPresto, a New Point of Care Device for the Enumeration of CD4% and Absolute CD4+ T Cell Counts in HIV Infection
title_fullStr Evaluation of the FACSPresto, a New Point of Care Device for the Enumeration of CD4% and Absolute CD4+ T Cell Counts in HIV Infection
title_full_unstemmed Evaluation of the FACSPresto, a New Point of Care Device for the Enumeration of CD4% and Absolute CD4+ T Cell Counts in HIV Infection
title_short Evaluation of the FACSPresto, a New Point of Care Device for the Enumeration of CD4% and Absolute CD4+ T Cell Counts in HIV Infection
title_sort evaluation of the facspresto, a new point of care device for the enumeration of cd4% and absolute cd4+ t cell counts in hiv infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936750/
https://www.ncbi.nlm.nih.gov/pubmed/27388763
http://dx.doi.org/10.1371/journal.pone.0157546
work_keys_str_mv AT makadzangeazuretariro evaluationofthefacsprestoanewpointofcaredevicefortheenumerationofcd4andabsolutecd4tcellcountsinhivinfection
AT bogezicarola evaluationofthefacsprestoanewpointofcaredevicefortheenumerationofcd4andabsolutecd4tcellcountsinhivinfection
AT boydkathryn evaluationofthefacsprestoanewpointofcaredevicefortheenumerationofcd4andabsolutecd4tcellcountsinhivinfection
AT gumboanesu evaluationofthefacsprestoanewpointofcaredevicefortheenumerationofcd4andabsolutecd4tcellcountsinhivinfection
AT mukuradorinda evaluationofthefacsprestoanewpointofcaredevicefortheenumerationofcd4andabsolutecd4tcellcountsinhivinfection
AT matubuallen evaluationofthefacsprestoanewpointofcaredevicefortheenumerationofcd4andabsolutecd4tcellcountsinhivinfection
AT ndhlovuchiratidzoellen evaluationofthefacsprestoanewpointofcaredevicefortheenumerationofcd4andabsolutecd4tcellcountsinhivinfection